What Happened?
Baltimore, MD-based Delfi Diagnostics Appointed Timothy McDaniel as Vice President of Technology Development
About the Company
Delfi is developing a new class of liquid biopsy tests for early detection based on altered genome-wide fragmentation profiles, also known as "fragmentomes," representing aberrant packaging of DNA in cancer cells. By applying advanced machine learning algorithms, these fragment patterns are detectable at a very low sequencing cost. Delfi is using this technology to develop highly sensitive and specific cancer detection assays intended for wide and cost-effective distribution and adoption.
About the Person
Timothy McDaniel is Vice President of Technology Development at Delfi Diagnostics. Previously, Timothy held various senior IT leadership roles in the industry.
Info Source
News
Short Profile